Deep 6 AI Announces Release of Trial Recommender
Deep 6 AI announced the addition of Trial Recommender to its artificial intelligence (AI)-driven clinical trial acceleration platform. Trial Recommender lets physicians and their patients easily discover and participate in clinical research.
Leveraging the Deep 6 AI and NLP platform, Trial Recommender offers precision-matched clinical trial opportunities for patients, during their visit with a treating physician, based on real-time structured and unstructured clinical data.
Starting inside their EMR or the Trial Recommender portal, a physician can review precision-matched trial opportunities for their patients to determine study fit and impact. This empowers doctors to give their patients access to treatments and make data-driven decisions about their care. Trial Recommender also operates across the Deep 6 site network.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
